Keeping HEALTHCARE PROFESSIONALS IN PRIMARY AND SECONDARY CARE updated.
BREAKING NEWS
To coincide with presentations at the 70th Scientific Sessions of the American Diabetes Association, the following articles were published on June 29, 2010, at NEJM.org.
The following Mixtard 30 presentations will be discontinued on December 31st 2010.
Mixtard Penfil 3ml cartridges
MIxtard 30 Innolet
Mixtard 30 10ml vial
Patients here in Leicester who are on the Mixtard 30 insulin are advised to speak to their Diabetes team at their Next appointment to discuss the changes to their treatment. The Diabetes specialist Nurses will be supporting Primary care with changing of patient treatment.
Please download the information leaflet from Novo Nordisk for more information
Wed 23rd June - NHS Health Checks Programme, the way ahead in Leicester
Wed 29th September - New therapies in cardiovascular disease & heart failure November meeting - still to be arranged
Change to lipid modification NICE guideline (CG67)
Changes have been made to the NICE guideline on 'Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease' (CG67). The changes relate to recommendations on methods of cardiovascular risk estimation. Description of change: Changes To Lipid Modification GuidelineCG67 Amended guideline Also See our NICE guidelines section
OBESITY STATISTICS
Obesity data briefings The National Obesity Observatory has published the following 'Key data briefings' which compile up-to-date information and data about obesity and its determinants in an easily readable format. They will be updated regularly and the series will be expanded to cover more factors that impact on obesity. - Adult weight - Child weight - Determinants of obesity: adult diet - Determinants of obesity: child diet - Determinants of obesity: adult physical activity - Determinants of obesity: child physical activity www.noo.org.uk
Drug alert: Glibenclamide 5mg tablets
The MHRA, via the Central Alerting System, has issued a Drug Alert class 3: Teva UK Limited are recalling some batches of Glibenclamide 5mg tablets in Teva UK Limited and Generics (UK) Limited livery as a precautionary measure because routine stability testing has indicated that the specification for tablet dissolution may not be met after 12 months from manufacture. Click here to access the MHRA link (15/3/10)
Exenatide may now be prescribed in primary care by prescribers who are competent to do so. A training program will be available for those who wish to prescribe exenatide and should be completed prior to prescribing it.
EXENATIDE TRIANING
If you are interested please contact: Anna Findlay e-mail:findlay_anna@lilly.com call/text: 0751 5296791
Mixtard 30 Discontinuation 31st Dec 2010